top of page

The FDA has expanded the indication for TMS for patients up to 86 years of age

Writer's picture: Benjamin GreenzweigBenjamin Greenzweig

Updated: Nov 25, 2024


The expanded approval was based on data from a postmarketing study that included 247 older patients (60 to 91 years of age) with MDD who underwent Deep TMS therapy.

Comments


bottom of page